HN21C0561

Development of a preclinical candidate of a UniStac-based long-acting tetra-specific drug for NASH

Onegene Biotechnology

ONEGENE BIOTECHNOLOGY

METABOLIC | **Candidate**

Product Type	Biological-Protein Product [Multi-specific drug]
Indication	1st indication: NASH, Cirrhosis 2nd indication: Idiopathic Pulmonary Fibrosis
Target	Glucagon-like peptide-1 [GLP-1], Glucagon [GCG], Fibroblast growth factor 21[FGF21], and α-Cytokine
MoA(Mechanism of Action)	
Competitiveness	Best-in-Class Efficacy: Improved efficacy and therapeutic window for the NASH and liver fibrosis resolution compared to the leading FGF21 asset Potential Accelerated Approval: High unmet need in reversing cirrhosis (F4) Potential Multi-Organ Anti-Fibrosis Treatment: Strong anti-fibrosis effect in IPF mouse model
Development Stage	Candidate
Route of Administration	Subcutaneous Administration

kddf_bd@kddf.org
KDDF Business Development Team

KDDF Korea Drug Development Fund